Hugo Fernandes, at the University of Oxford, is working to understand the role of fats and the progression of dementia.

Donanemab has been licensed in the UK as a treatment for early-stage Alzheimer’s but is only available privately, not through the NHS. Here's what we know about this new Alzheimer's drug.

New dementia drugs can only be developed with the help of people who volunteer to take part in research. 

Melissa Parra Torres, a PhD student at the University of Dundee, wants to help find new ways to diagnose dementia and slow its progress.

Lecanemab made headlines as the first MHRA-approved drug in the UK to slow early-stage Alzheimer’s disease, but it has not been recommended for NHS at this stage. Here is what we know so far about this breakthrough Alzheimer's drug. 

In July 2024, Alzheimer’s Society launched the Dementia Healthcare Inequalities Initiative. We sat down with Professor Jennie Popay, the Chair of our Healthcare Inequalities Advisory Board to hear more about the innovative research applications she hopes to see.

People living with Alzheimer’s are helping researchers to test a brain stimulation technique that could lead to future treatments. 

Dementia Research Leader Kamen Tsvetanov is working to understand brain resilience and how the brain adapts to change.